Enanta Pharmaceuticals (ENTA) vs Rocket Pharmaceuticals (RCKT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Rocket Pharmaceuticals (RCKT) has outperformed Enanta Pharmaceuticals (ENTA) over the past year, losing 33.4% versus a loss of 40.1%. Over five years, ENTA leads with a -91.7% price change compared with -91.8% for RCKT. Enanta Pharmaceuticals is the larger company by market cap ($222.2 million vs $217.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ENTA | RCKT |
|---|---|---|
| Share price | $7.62 | $1.95 |
| Market cap | $222.19M | $217.74M |
| 1-day change | -4.51% | -7.58% |
| YTD return | -51.68% | -44.44% |
| 1-year return | -40.14% | -33.45% |
| 5-year return | -91.71% | -91.76% |
| EPS (TTM) | $-2.35 | $-0.15 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $63.00M | $0 |
| Revenue growth (YoY) | -3.56% | — |
| Net income (latest FY) | $-68.25M | $-223.12M |
| Operating margin | -99.01% | — |
| Net margin | -108.33% | — |
| 52-week high | $17.15 | $5.45 |
| 52-week low | $7.56 | $1.94 |
| Distance from 52-week high | -55.57% | -64.22% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +186.48% | +326.15% |
| Average volume | 287.81K | 1.90M |
| Shares outstanding | 29.16M | 111.66M |
| Employees | 120 | 202 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Enanta Pharmaceuticals
ENTA stock →Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 120 employees
About Rocket Pharmaceuticals
RCKT stock →Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States. It develops in vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), which is in phase 1; and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is a form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart, which is in preclinical stage.
Health Care · Biotechnology: Pharmaceutical Preparations · 202 employees
ENTA vs RCKT FAQ
Which is bigger, Enanta Pharmaceuticals or Rocket Pharmaceuticals?
Enanta Pharmaceuticals (ENTA) is larger, with a market capitalization of $222.19M compared with $217.74M for Rocket Pharmaceuticals (RCKT).
Which stock has performed better over the past year, ENTA or RCKT?
RCKT returned -33.45% over the past 12 months, compared with -40.14% for ENTA (price return, excluding dividends). Past performance does not predict future results.
Are Enanta Pharmaceuticals and Rocket Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.